Foetal and neonatal alloimmune thrombocytopaenia

Kaplan, Cecile
January 2006
Orphanet Journal of Rare Diseases;2006, Vol. 1, p39
Academic Journal
Foetal/neonatal alloimmune thrombocytopaenia (NAIT) results from maternal alloimmunisation against foetal platelet antigens inherited from the father and different from those present in the mother, and usually presents as a severe isolated thrombocytopaenia in otherwise healthy newborns. The incidence has been estimated at 1/800 to 1/1 000 live births. NAIT has been considered to be the platelet counterpart of Rh Haemolytic Disease of the Newborn (RHD). Unlike RHD, NAIT can occur during a first pregnancy. The spectrum of the disease may range from sub-clinical moderate thrombocytopaenia to life-threatening bleeding in the neonatal period. Mildly affected infants may be asymptomatic. In those with severe thrombocytopaenia, the most common presentations are petechiae, purpura or cephalohaematoma at birth, associated with major risk of intracranial haemorrhage (up to 20% of reported cases), which leads to death or neurological sequelae. Alloimmune thrombocytopaenia is more often unexpected and is usually diagnosed after birth. Once suspected, the diagnosis is confirmed by demonstration of maternal antiplatelet alloantibodies directed against a paternal antigen inherited by the foetus/neonate. Post-natal management involves transfusion of platelets devoid of this antigen, and should not be delayed by biological confirmation of the diagnosis (once the diagnosis is suspected), especially in case of severe thrombocytopaenia. Prompt diagnosis and treatment are essential to reduce the chances of death and disability due to haemorrhage. Due to the high rate of recurrence and increased severity of the foetal thrombocytopaenia in successive pregnancies, antenatal therapy should be offered. However, management of high-risk pregnancies is still a matter of discussion.


Related Articles

  • Rare Disorders and Diseases.  // Exceptional Parent;Aug2008, Vol. 38 Issue 8, p26 

    The article discusses various reports published within the issue, including 22q11 deletion syndrome by Mary Umlauf, and another about isovaleri acidemia by Jana Monaco.

  • Primary sclerosing cholangitis. Worthington, Joy; Chapman, Roger // Orphanet Journal of Rare Diseases;2006, Vol. 1, p41 

    Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown aetiology characterised by inflammation and fibrosis of the biliary tree. The mean age at diagnosis is 40 years and men are affected twice as often as women. There is a reported annual incidence of PSC of 0.9-...

  • Congenital pulmonary lymphangiectasia. Bellini, Carlo; Boccardo, Francesco; Campisi, Corradino; Bonioli, Eugenio // Orphanet Journal of Rare Diseases;2006, Vol. 1, p43 

    Congenital pulmonary lymphangiectasia (PL) is a rare developmental disorder involving the lung, and characterized by pulmonary subpleural, interlobar, perivascular and peribronchial lymphatic dilatation. The prevalence is unknown. PL presents at birth with severe respiratory distress, tachypnea...

  • Ultra orphan drugs and diseases. Kumar, D.; Gupta, S. // Indian Journal of Pharmacology;Oct2006, Vol. 38 Issue 5, p375 

    The article presents a letter focusing on various aspects of orphan diseases and drugs. Ultra orphan drugs are considered to be drugs which are used in treating rare and debilitating diseases. In has been stressed that ultra orphan disease refers to diseases with less than 0.18 case per 10,000...

  • Síndrome antifosfolípido y necrosis suprarrenal, reporte de dos casos y revisión de la literatura científica. FERNÁNDEZ BONILLA, J. NICOLÁS; JARAMILLO GARCÍA, LUIS FERNANDO; ESCALANTE, PAOLA // Universitas Médica;abr-jun2011, Vol. 52 Issue 2, p219 

    Antiphospholipid syndrome is a disease that can manifest alone or associated with other conditions. Adrenal glands involvement is a rare presentation. There are few cases reported in the literature. We present two cases of patients with antiphospholipid syndrome that compromise the adrenal...

  • Distributional interaction: Interpretational problems when using incidence odds ratios to assess interaction. Campbell, Ulka B.; Gatto, Nicolle M.; Schwartz, Sharon // Epidemiologic Perspectives & Innovations;2005, Vol. 2, p1 

    It is well known that the incidence odds ratio approximates the risk ratio when the disease of interest is rare, but increasingly overestimates the risk ratio as the disease becomes more common. However when assessing interaction, incidence odds ratios may not approximate risk ratios even when...

  • Human Tularemia in France, 2006-2010. Maurin, Max; Pelloux, Isabelle; Brion, Jean Paul; Del Banõ, Jeanne-Noëlle; Picard, Aleth // Clinical Infectious Diseases;11/15/2011, Vol. 53 Issue 10, pe133 

    Background. Tularemia is an endemic but rare disease in France. We describe the epidemiologic, clinical, diagnostic, treatment, and prognostic aspects of the disease in 101 consecutive patients investigated during a 5-year period (2006-2010). Methods. All tularemia cases confirmed at the French...

  • Cochlear implantation is safe and effective in patients with MYH9-related disease. Pecci, Alessandro; Verver, Eva J. J.; Schlegel, Nicole; Boccio, Carlos M.; Platokouki, Helen; Krause, Eike; Benazzo, Marco; Topsakal, Vedat; Greinacher, Andreas; Canzi, Pietro // Orphanet Journal of Rare Diseases;2014, Vol. 9 Issue 1, p2 

    Background MYH9-related disease (MYH9-RD) is a rare syndromic disorder deriving from mutations in MYH9, the gene for the heavy chain of non-muscle myosin IIA. Patients present with congenital thrombocytopenia and giant platelets and have a variable risk of developing sensorineural deafness,...

  • Rare disease day, conference 29.2.2012 - Presentations.  // Acta Facultatis Pharmaceuticae Universitatis Comenianae;2012 Supplement 7, Vol. 59, p9 

    The article discusses several studies including "National Registry for Cystic Fibrosis (CF) in Slovakia" "Slovak Alliance of Rare Diseases (Slovak RD Alliance), " and "Orphan Drugs: The Approach of European and Slovak Regulatory Institutions." These researches feature several rare diseases, and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics